Pharmahungary Group Founder & CEO appointed as Editor-in-Chief of the British Journal of Pharmacology
Pharmahungary Group Founder & CEO, Prof. Péter Ferdinandy, MD, PhD, MBA has been appointed as Editor-in-Chief of the British Journal of Pharmacology (BJP). Prof. Ferdinandy will serve as Editor-in-Chief from January 1st, 2023 of BJP, one of the most prestigious journals in pharmacology with an impact factor of 9,5. Professor Ferdinandy said that during his time as Editor-in-Chief his main aim is to “drive science and innovations in all areas of pharmacology in the 21st century”.
President of the British Pharmacological Society Professor Clive Page said: ““I am delighted to welcome Péter to the team. His experience as a Senior Editor and demonstrable leadership within the pharmacology community will ensure the Journal goes from strength to strength, providing a place to publish for all pharmacology researchers, growing our reach and impact.”
Prof. Ferdinandy is considered one of the worldwide key opinion leaders in pharmacology of cardioprotection. Besides being the CEO of a successful group of R&D companies he is also the Vice-Rector for Science and Innovations and Professor and Director of the Department of Pharmacology and Pharmacotherapy at Semmelweis University, Budapest, Hungary as well as the President of the Hungarian Society of Pharmacology and Executive Committee member of the European Federation of Pharmacological Societies.
For more information on the innovative preclinical and clinical R&D services of Pharmahungary Group please visit www.pharmahungary.com or contact us directly at email@example.com.